LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced it has signed a term sheet with 5Horizons Ventures, LLC, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing. The agreement facilitates the formation of an investment syndicate to fund LPOXY's registrational STOP-Cdiff (SIDIPREV™ Trial On Prevention of C. difficile Infections) clinical trial.